Biologics have revolutionized the treatment and prevention of many disabling and life-threatening diseases.
However, biologics are contributing to the rising costs of healthcare, and this may restrict access to these important medicines.
A biosimilar is an approved biologic with comparable quality, safety and efficacy to an approved reference product.
Biosimilars can liberate healthcare resources and help more patients experience the life-enhancing benefits of biologic treatment.
Sandoz, the pioneer and global leader in biosimilars
Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global leader in biosimilars, with three marketed products: Binocrit®, Omnitrope®, Zarzio®/Zarxio®, Rixathon® and Erelzi®.
With a leading pipeline, Sandoz plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020. This will be enabled by 11 filings over a three-year period (2015-2017). Sandoz’ early-stage pipeline has additional assets in oncology as well as other specialty therapeutic areas with plans to start new programs every year.
As a division of the Novartis Group, Sandoz is well-positioned to lead the biosimilars industry based on its experience and capabilities in development, manufacturing and commercialization.
® : Registered trademark owned or used under license by Sandoz Canada Inc.